Phase II Failure – Talk Bio

Actionable Insights Powered by AI

Ipsen’s Fidrisertib Fails Primary Endpoint in Pivotal Phase II FALKON Trial for Rare Bone Disease FOP

Ipsen; fidrisertib; FALKON trial; FOP; Phase II failure; heterotopic ossification